Investors Asset Management of Georgia Inc. GA ADV Cuts Holdings in Eli Lilly and Company $LLY

Investors Asset Management of Georgia Inc. GA ADV lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,886 shares of the company’s stock after selling 105 shares during the quarter. Eli Lilly and Company makes up 2.5% of Investors Asset Management of Georgia Inc. GA ADV’s portfolio, making the stock its 6th biggest position. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Eli Lilly and Company were worth $5,368,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Gratus Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 5.4% in the second quarter. Gratus Wealth Advisors LLC now owns 1,737 shares of the company’s stock valued at $1,354,000 after acquiring an additional 89 shares in the last quarter. Valley National Advisers Inc. lifted its position in shares of Eli Lilly and Company by 5.4% in the 2nd quarter. Valley National Advisers Inc. now owns 4,835 shares of the company’s stock worth $3,767,000 after purchasing an additional 246 shares during the period. Duncan Williams Asset Management LLC boosted its stake in shares of Eli Lilly and Company by 29.6% during the 2nd quarter. Duncan Williams Asset Management LLC now owns 328 shares of the company’s stock valued at $256,000 after purchasing an additional 75 shares in the last quarter. Autumn Glory Partners LLC increased its position in shares of Eli Lilly and Company by 48.5% during the second quarter. Autumn Glory Partners LLC now owns 1,044 shares of the company’s stock valued at $814,000 after buying an additional 341 shares during the period. Finally, Fishman Jay A Ltd. MI lifted its holdings in Eli Lilly and Company by 54.2% in the second quarter. Fishman Jay A Ltd. MI now owns 6,094 shares of the company’s stock worth $4,750,000 after buying an additional 2,143 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $840.46 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The firm’s 50-day moving average is $734.60 and its 200 day moving average is $765.44. The stock has a market cap of $795.46 billion, a price-to-earnings ratio of 54.93, a PEG ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the company earned $3.92 earnings per share. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LLY. HSBC increased their target price on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a research report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $938.94.

Insiders Place Their Bets

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 in the last three months. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.